Page 24 - Sequencing News Today

Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.

Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.

Saskatoon, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SASKATOON — World-class talent and sequencing technology at the Global Institute for Food Security (GIFS) at...

INTEGRA Biosciences is excited to announce the launch of MIRO CANVAS, a compact digital microfluidics platform for fully automated next generation sequencing (NGS) sample preparation. Click to read more...

Integra Biosciences introduces MIRO CANVAS, a compact digital microfluidics platform designed to fully automate next-generation sequencing (NGS) sample preparation. Click to read more...

Qatar completes genome sequencing of 30,000 citizens

MGI Tech Singapore Pte, Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore ("NCCS") to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI's core DNBSEQ™ technology. The collaboration is one of many examples of MGI's efforts in empowering personalized medicine and precision oncology with its in...

Seven states have identified the omicron subvariant BA.2.86 as of Sept. 13, according to data from outbreak.info.

Download this Gene Expression and Regulation eBook to explore how next-generation sequencing (NGS) is accelerating high impact studies using bulk or single-cell RNA-Seq applications.

The NovaSeq™ 6000Dx is Illumina’s first IVD-compliant high-throughput sequencing instrument for the clinical lab. Push the boundaries of clinical genomics with scalable throughput and improved economics like never before.